Article Details

China's Yisheng Biopharma nets $130m in Series B round co-led by OrbiMed

Retrieved on: 2021-02-24 09:00:00

Tags for this article:

Click the tags to see associated articles and topics

China's Yisheng Biopharma nets $130m in Series B round co-led by OrbiMed. View article details on hiswai:

Excerpt

China's Yisheng Biopharma Ltd has closed its $130-million Series B round co-led by returning investor OrbiMed and deep tech-focused investor ...

Article found on: www.dealstreetasia.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo